Impact of Biofield Energy Treated DMEM on Mitochondrial Biogenesis Using Myoblast Cell Line, C2C12: Implications for Metabolic Disease

Journal: International Journal of Biochemistry & Physiology  

Published: February 19, 2019 Volume: 4 Issue: 1 Pages: 1-7

DOI: 10.23880/ijbp-16000146 ISSN: 2577-4360

Authors: Trivedi MK and Jana S

Citation: Trivedi MK and Jana S. Impact of Biofield Energy Treated DMEM on Mitochondrial Biogenesis Using Myoblast Cell Line, C2C12: Implications for Metabolic Disease. Int J Biochem Physiol 2019, 4(1): 000146.

  • 89 Views
  • 6 Downloads

Abstract

Mitochondria play an important role in the body, and its dysfunction lead to the defective cellular energy production results to heterogeneous group of disorders such as early aging, type-2 diabetes, Alzheimer’s disease, and many more metabolic diseases. The study was aimed to examine the effect of Consciousness Energy Healing based DMEM on myoblasts cells (C2C12) for mitochondrial mass content. The test item, DMEM was divided into three parts. First part did not receive any sort of treatment and defined as the untreated DMEM group. The second and third portions were treated with the one-time and two-times Biofield Energy Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and coded as the one-time Biofield Energy Treated DMEM (BT-I) and two-times Biofield Energy Treated DMEM (BT-II) groups, respectively. Cell viability of the test items by MTT assay showed more than 72% viable cells, which suggested that the test items were nontoxic and safe in nature. Moreover, the mitochondrial mass content in terms of fluorescence unit (FU) was significantly (p≤0.05) increased by 43.11% and 64.16% in the BT-I and BT-II groups, respectively in C2C12 cells compared to the untreated DMEM group. Overall, the experimental data suggested that twotimes treated DMEM (BT-II) was found more significant improvement in mitochondrial mass content compared with the one-time treated DMEM (BT-I) group and results in better respiratory capacity. Thus, data envisaged that the Biofield Energy Treated DMEM has a potential to improve respiratory activity, which could be used against various metabolic diseases, such as insulin resistance, type-2 diabetes, and cardiovascular diseases, etc.

Conclusion

The MTT assay data showed a significant improvement in cell viability by 123% and 129% in the one-time treated DMEM (BT-I) and two-times treated DMEM (BT-II) groups, respectively in C2C12 cells. Besides, the mitochondrial mass content was significantly (p≤0.05) increased by 43.11% and 64.16% in the BT-I and BT-II groups, respectively compared to the untreated DMEM group. Overall, the Biofield Energy Treated DMEM significantly improved mitochondrial mass content, and that results in the better respiratory activity. Thus data anticipated that it could be used to improve the energy level, endurance, body energy, which can be utilized against many metabolic diseases such as aging, diabetes, cancer, depression, hypertension, cardiovascular disease, and physical strength. Thus, the Biofield Energy Healing based DMEM might be a suitable alternative for cell growth and development. It can be further useful for the management of numerous disorders such as Systemic Lupus Erythematosus, Addison Disease, Reactive Arthritis, Multiple Sclerosis, Dermatomyositis, Rheumatoid Arthritis, Graves’ Disease, Hashimoto Thyroiditis, Pernicious Anemia, Aplastic Anemia, Scleroderma, Crohn’s Disease, Psoriasis, Diabetes, Myasthenia Gravis, Chronic Fatigue Syndrome, Vitiligo, Alopecia Areata, and Vasculitis, Irritable Bowel Syndrome, Asthma, Alzheimer’s Disease, Dermatitis, Parkinson’s Disease, Hepatitis, Ulcerative Colitis, Atherosclerosis, and Diverticulitis. Further, Biofield Energy Healing Treatment can also be used in the prevention of immune-mediated tissue damage in cases of organ transplants (for example kidney transplants, heart transplants, and liver transplants), stress, anti-aging, etc.